Cargando…

Association of Triglyceride Deposit Cardiomyovasculopathy With Drug-Eluting Stent Restenosis Among Patients With Diabetes

This cohort study uses data from a single-center cardiac catheter database to investigate the association of cardiac stent restenosis in patients with diabetes mellitus and comorbid triglyceride deposit cardiomyovasculopathy.

Detalles Bibliográficos
Autores principales:	Nakano, Yusuke, Suzuki, Mayu, Hirano, Ken-ichi, Ando, Hirohiko, Takashima, Hiroaki, Takahashi, Hiroshi, Amano, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414388/ https://www.ncbi.nlm.nih.gov/pubmed/32766797 http://dx.doi.org/10.1001/jamanetworkopen.2020.12583

Ejemplares similares

Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients
por: Onishi, Tomohiro, et al.
Publicado: (2021)

Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder
por: Li, Ming, et al.
Publicado: (2019)

Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy
por: Hirano, Ken-ichi, et al.
Publicado: (2022)

Triglyceride Deposit Cardiomyovasculopathy with Massive Myocardial Triglyceride which Was Proven Using Proton-magnetic Resonance Spectroscopy
por: Sai, Eiryu, et al.
Publicado: (2020)

Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovasculopathy
por: Hara, Yasuhiro, et al.
Publicado: (2013)

A novel homozygous missense mutation in PNPLA2 in a patient manifesting primary triglyceride deposit cardiomyovasculopathy
por: Hara, Yasuhiro, et al.
Publicado: (2023)

Methods of calculating (123)I-β-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy
por: Chen, Zhuoqing, et al.
Publicado: (2022)

(1)H-MRS to evaluate improved triglyceride accumulation in idiopathic triglyceride deposit cardiomyovasculopathy after CNT-01 (tricaprin/trisdecanoin) administration
por: Aikawa, Tatsuro, et al.
Publicado: (2023)

Peripheral leukocyte anomaly detected with routine automated hematology analyzer sensitive to adipose triglyceride lipase deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy
por: Suzuki, Akira, et al.
Publicado: (2014)

ATGL Deficiency-Induced Triglyceride Deposit Cardiomyovasculopathy Requiring Heart Transplant: A 5-Year Follow-Up
por: Rajani, Prina, et al.
Publicado: (2020)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis
por: Abdelmegid, Mohamed Aboel-Kassem F., et al.
Publicado: (2017)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Dynamic Changes in Coronary Flow Pattern During Transcatheter Aortic Valve Replacement in Severe Aortic Stenosis
por: Suzuki, Wataru, et al.
Publicado: (2021)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

Impact of the Distance from the Stent Edge to the Residual Plaque on Edge Restenosis following Everolimus-Eluting Stent Implantation
por: Takahashi, Masao, et al.
Publicado: (2015)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
por: PARK, CHANG-BUM, et al.
Publicado: (2013)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

Rheocarna(®) as an alternative therapeutic option for patients with chronic limb-threatening ischemia: A case report
por: Satake, Akinori, et al.
Publicado: (2023)

In-Stent Restenosis Exacerbated by Drug-Induced Severe Eosinophilia after Second-Generation Drug-Eluting Stent Implantation
por: Yagi, Hiroki, et al.
Publicado: (2014)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

Intravascular Ultrasound-Guided Treatment for In-stent Restenosis Associated with Stent Fracture in Overlapped Drug-eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2019)

Impact of ivabradine in decompensated heart failure due to cancer therapy‐related cardiac dysfunction
por: Nakano, Yusuke, et al.
Publicado: (2021)

Impact of Exercise-based Cardiac Rehabilitation on In-stent Restenosis with Different Generations of Drug Eluting Stent
por: Kim, Chul, et al.
Publicado: (2012)

Local drug-delivery balloon for proliferative occlusive in-stent restenosis after drug-eluting stent
por: Rigatelli, Gianluca, et al.
Publicado: (2011)

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents
por: Yin, Jiasheng, et al.
Publicado: (2017)

In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario
por: Paramasivam, Ganesh, et al.
Publicado: (2019)

Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation
por: Luo, Yinhua, et al.
Publicado: (2022)

Effect of Atorvastatin-Eluting Stents in a Rabbit Iliac Artery Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_73tcgg12cp94q85pc632jqa3pm